Pharmacological and/or surgical closure of a hemodynamically significant patent ductus arteriosus (PDA) in the very preterm infant has been the standard of care over the past few decades. However, the ...

Please provide your email address to receive an email when new articles are posted on . Early screening echocardiography for patent ductus arteriosus in preterm infants was associated with lower rates ...

Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

SHOULD closure of a patent ductus arteriosus with reversal of flow be attempted? If so, how can the high surgical mortality hitherto reported 1–3 be reduced? An attempt is made to answer these ...

This article presents common misconceptions about the physiologic significance of early ductal shunting and reviews the evidence regarding the preferential use of echocardiography rather than reliance ...

Among extremely preterm infants, early screening for the vascular disorder patent ductus arteriosus before day 3 of life was associated with a lower risk of in-hospital death and pulmonary hemorrhage, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

(HealthDay News) — Early treatment to induce closure of the patent ductus arteriosus (PDA) in preterm infants does not improve long-term outcomes, according to a clinical report published online ...

The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants. Whether selective early treatment of large PDAs with ibuprofen would improve short-term ...

The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...

The US Food and Drug Administration has cleared the smallest occlusion device to date for the treatment of symptomatic patent ductus arteriosus (PDA) in premature infants, device manufacturer Abbott ...